Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism

Initial management of deep venous thrombosis in the outpatient setting

“…However, the study had a number of limitations. [29][30][31] Notably, three fourths of patients given a LMWH received dalteparin, which is not labeled for VTE treatment unless for long-term treatment in patients with cancer, and published data demonstrating efficacy over i.v. UFH are limited.…”

“…These limitations and the lack of additional reports on the use of subcutaneous UFH for the treatment of DVT suggest that the use of subcutaneous UFH without aPTT monitoring for outpatient treatment may be premature. [29][30][31] Secondary VTE prevention in cancer patients. Long-term treatment of VTE ("secondary VTE prevention") already occurs in the outpatient setting with warfarin.…”